



Liz Dávila
NuGEN Technologies, Inc.
650.590.3610
ldavila@nugeninc.com

Media contact:
Richard A. Howell
SVM Group for NuGEN
650.346.7425
rhowell@svmgroup.com

NuGEN Technologies Appoints Elizabeth A. Hutt Chief Executive Officer

Anne R. Kopf-Sill Promoted to Senior Vice President of Product Development and Operations

SAN CARLOS, Calif. – September 12, 2005 – NuGEN, Technologies, Inc., a privately held company that develops and commercializes the new standard in nucleic acid amplification and labeling systems, today announced that Ms. Elizabeth A. Hutt has been appointed the Chief Executive Officer effective November 1st. Ms. Hutt will lead the company in the development and commercialization of its leading nucleic acid amplification and detection technologies. NuGEN's current acting CEO, Ms. Elizabeth Dávila, will remain a member of the company's board of directors. Dr. Anne R. Kopf-Sill, previously vice president of product development, has been promoted to senior vice president of product development and operations.

Ms. Hutt was previously NuGEN's vice president of commercial operations and brings fifteen years of leadership experience in diversified sales, marketing, business development, and technical support. Prior to joining NuGEN, Ms. Hutt was vice president of sales and service, North America and Pacific Rim at Tripos, Inc., a leader in molecular modeling software. She has held U.S. and European sales management positions with Affymetrix Inc. and spent over 9 years in sales, marketing and channel management at Life Technologies, Inc. (now Invitrogen). Ms. Hutt received her B.A. in Chemistry from Michigan State University and a M.S. in Business Administration from Central Michigan University.

"Ms. Hutt brings a track record of executive leadership experience to NuGEN," said James N. Wilson, chairman of the board of directors for NuGEN. "As CEO, she will focus on NuGEN's short and long-term objectives of increasing revenue, expanding technology and product portfolios, and positioning the company for increased growth and expansion."

Dr. Kopf-Sill brings over fifteen years of experience in developing increasingly complex research and diagnostic products to her new role, in which she will continue to drive new product development. In addition, she will also lead the rapid expansion of manufacturing operations. Prior to joining NuGEN, Dr. Kopf-Sill held senior positions with Caliper, Abaxis, and Molecular Devices. She is an inventor on more than 30 microfluidics and diagnostic patents and has a B.S. in Chemical Engineering from the University of Virginia and a Ph.D. in Chemical Engineering from Stanford University.

"Dr. Kopf-Sill's strong scientific credentials and her proven achievements in developing innovative products for NuGEN are a combination that will provide key leadership for our continuing growth and success," said James N. Wilson, chairman of the board of directors for NuGEN.

About NuGEN Technologies Inc.

NuGEN Technologies is focused on the development and commercialization of sensitive, rapid and cost-effective amplification and detection systems for genomic and proteomic research. The company's technologies enable the comprehensive analysis and discovery of biological mechanisms, cellular responses, and disease pathologies. NuGEN's proprietary SPIA™ and Ribo-SPIA™ amplification and labeling system for DNA and RNA based applications, form the foundation for a wide range of methods and products used by life scientists. The Ovation™ amplification and labeling system, the company's first commercially available product line, has applied these technologies to enhancing the sensitivity, convenience, and accuracy of gene expression analysis. Based in



San Carlos, CA, NuGEN has a world-class investor syndicate, several collaborations with leading academic and commercial organizations and a management team with significant experience developing and marketing products for research or clinical diagnostic applications.

NuGEN, Ovation, SPIA and Ribo-SPIA are trademarks or service marks of NuGEN Technologies, Inc. All other marks are the property of their respective owners.

This press release contains forward-looking statements that are subject to risks and uncertainties, including continued growth in demand by researchers for total RNA analysis, continued use of oligo and cDNA microarrays, acceptance by researchers of the Company's technologies and products, and competition from existing and newly developed products. Accordingly, actual results may differ materially from those anticipated. These forward-looking statements represent the Company's current expectations as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

###